RxDoctor Payments Data

Rupa Shah, MD

Ophthalmology · Cleveland, OHNPI 1649439746

Payments from drug & device makers

$1,956in general payments, 2019–2025

Across 91 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$655
  • Biotissue Holdings Inc.$380
  • AbbVie$277
  • Bausch & Lomb Americas Inc.$186
  • Sun Pharmaceutical Industries Inc.$131
  • Tarsus Pharmaceuticals, Inc.$121
  • plus $205 from 5 others

What the payments were for

  • Food & beverage$1,93999%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,956 in reported general payments places this provider in the 60th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$271,569
Medicare patients
428
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast78$66,734
RestasisCyclosporine77$64,062
MieboPerfluorohexyloctane/Pf27$27,425
Prednisolone Acetate873$22,982
TyrvayaVarenicline Tartrate12$12,099
Cyclosporine18$8,987
ProlensaBromfenac Sodium16$5,529
Ketorolac Tromethamine272$3,548
Ofloxacin361$3,362
CombiganBrimonidine Tartrate/Timolol11$1,781
Difluprednate30$1,380
ValacyclovirValacyclovir Hcl17$1,320
Acyclovir36$1,291
Fluorometholone25$1,268
MoxifloxacinMoxifloxacin Hcl39$1,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$186$94,159105 claims
AbbVieRestasis, Combigan$277$65,84388 claims
Oyster Point Pharma, Inc.Tyrvaya$69$12,09912 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$13$5,52916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →